---

Highlights of June 2019

1. Dr. Reddy’s sells two neurology brands to Upsher-Smith for US$110 Million.
2. Glenmark signs deal with Novartis for 3 respiratory products in Brazil.
3. Sun Pharma enters licensing agreement with China Medical System Holdings.
4. Merck inks US$773 Million Tilos takeout to bag TGF? cancer programs.
5. Blue Earth Diagnostics sold to Bracco Imaging in US$450 Million deal.
6. Vertex makes US$420 Million preclinical play for DMD gene editing field.
7. J&J bags US$150 Million option on Genmab's Darzalex successor.
8. Almirall hands over US$50 Million for European rights to Dermira's Dupixent challenger.
9. Lilly announces licensing agreement for Non-Opioid Pain Asset from Centrexion Therapeutics with an upfront payment of US$47.5 Million.
10. Gilead taps Nurix's protein degradation tech in US$45 Million cancer pact.
11. Terumo plans to take Orchestra BioMed's sirolimus balloon international in US$35 Million deal.
12. Camargo Pharmaceutical services to Acquire Montreal-based InSymbiosis.

Updates at Aagami: 

• New Client Win: A Belgium based synthetic biology specialist company developing original genetic technologies using bacteriocins has appointed Aagami to support out-licensing of their 2 key patented technologies which increase yield and remove contamination.
• Aagami completed a highly successful BIO 2019 with several productive one-on-one strategic meetings with ‘C’ level professionals for Aagami and its clients.
• Aagami is going to attend Bio-Europe again in November 2019 (Hamburg, Germany).